🇺🇸

US SEC Filing Intelligence

· monthly

US Pre-Market SEC Filings Roundup — September 23, 2026

Overnight SEC filings reveal a market bifurcated between aggressive corporate expansion and defensive capital management. Royal Caribbean's $3.0B acquisition of a 50% stake in Sandals/Beaches Resorts and VNET's $659.5M acquisition by PJ Millennium highlight significant M&A activity, while multiple insider sales under 10b5-1 plans (Abacus, Webull, Qualys) signal potential valuation concerns in tech and financial sectors. Positive clinical and regulatory catalysts emerged from Ionis/Roche (sefaxersen Phase 3 hit) and AstraZeneca (EU approval for Trixeo), offering clear upside for healthcare investors. Capital-raising activities are prominent, with Millrose pricing $1.0B in senior notes and HPS funds reporting strong NAV growth and distributions. However, risk flags include Crona Corp's widening losses and zero revenue, Ocugen's shareholder dilution proposal, and Algorhythm's material agreement termination. Sector themes point to continued M&A in travel/leisure, insider selling in growth tech, and robust capital deployment in BDCs and energy infrastructure.

31 high priority 19 medium 50 total filings
· daily

Biotech Small-Cap Approvals — September 22, 2026

The September 22, 2026, small-cap biotech approvals stream delivered three generic/biosimilar-equivalent approvals (EPINEPHRINE from DIFGEN PHARMS, MILNACIPRAN HYDROCHLORIDE from STRIDES PHARMA, and TRETINOIN from ZYDUS LIFESCIENCES), with zero NMEs, zero label expansions, and no true biosimilar designations. The dominant theme is a low-innovation, high-volume genericization wave across established molecules, signaling margin compression rather than growth. The highest-conviction signal is the neutral-to-negative competitive pressure on originators of these mature drugs, as the approvals add supply without novel clinical value. Key watch item is the potential for accelerated price erosion across these three molecules, though commercial impact remains NOT_DISCLOSED. Overall, this is a non-event for pipeline-driven investors, but a modest headwind for originator franchises.

3 total filings
· daily

Big Pharma Approvals — September 22, 2026

This period includes a single label expansion approval for AstraZeneca's CAPIVASERTIB (TRUQAP), categorized as a 'fallback' approval with a bullish signal. No NMEs, biosimilars, or other label expansions were approved, making this a low-volume but still notable event for AstraZeneca's oncology franchise. The dominant signal is the label expansion's potential to broaden CAPIVASERTIB's commercial application, though peak sales, pricing power, and market position remain undisclosed. The key risk is the 'fallback' designation, which may imply a less transformative expansion than a typical label update, limiting investor conviction. Investors should monitor AstraZeneca's subsequent pipeline catalysts to offset this period's thin approval cadence.

1 total filings
· daily

Orphan Drug Approvals — September 22, 2026

During the period of September 22, 2026, one orphan drug approval was recorded, classified as 'Other' with no NMEs, biosimilars, or label expansions. The sole approval was a label expansion for TALETRECTINIB ADIPATE (IBTROZI) by NUVATION, which received a bullish signal. This expansion underscores NUVATION's strategic focus on broadening the clinical utility of its oncology asset, though the lack of disclosed commercial details limits the depth of investment analysis. The dominant therapeutic area theme is oncology, with a single but notable signal of label expansion as a growth strategy. The highest-conviction signal is the label expansion itself, indicating NUVATION's commitment to maximizing the drug's lifecycle value. Key watch items include the absence of disclosed peak sales estimates, exclusivity terms, and pricing power, which are critical for assessing commercial potential.

1 total filings
· daily

New Drug Approvals (Original) — September 22, 2026

The September 22, 2026, FDA approval stream delivered zero NMEs, zero biosimilars (per the mix classification), and three 'Other' approvals—all generic/biosimilar-type products from DIFGEN PHARMS (EPINEPHRINE), STRIDES PHARMA (MILNACIPRAN HYDROCHLORIDE), and ZYDUS LIFESCIENCES (TRETINOIN). This is a low-velocity, low-catalyst period with no therapeutic area clustering; the three approvals span acute allergy, neuropathic pain/depression, and acne/leukemia, respectively. The highest-conviction signal is the TRETINOIN approval by ZYDUS LIFESCIENCES, given the drug's dual dermatology/oncology use and the competitive dynamics in the generic retinoid space, though commercial impact remains NOT_DISCLOSED. Key risk: these are all 'FALLBACK' approvals with no disclosed exclusivity or pricing power, suggesting limited differentiation and potential margin compression. Investors should treat this as a non-event for portfolio positioning, with no bullish or bearish catalysts identified.

3 total filings
· daily

VA Healthcare & Services Contracts — September 22, 2026

The sole contract in this digest is a $240.6 million firm-fixed-price delivery order awarded to QTC Medical Services Inc., a Leidos subsidiary, by the Department of Veterans Affairs (VA) for medical evaluation and screening services under NAICS 621111. This is a purely civilian award with zero defense-related exposure, reflecting the VA's sustained investment in healthcare delivery rather than technology or defense priorities. The contract's 97% outlay rate ($233.6 million of $240.6 million) signals near-complete funding utilization and strong execution, but the neutral signal strength (5/10) and lack of options or set-asides temper the investment significance. The highest-conviction signal is the competitive win for Leidos in the VA healthcare services market, though the one-year performance period (Oct 2023–Sep 2024) has already elapsed, making follow-on recompete activity the key forward-looking catalyst. Key risks include concentration in a single agency and the absence of growth options, while the watch item is the timing and outcome of the follow-on procurement after September 2024.

1 total filings
· daily

New Federal Contractors — September 22, 2026

The sole contract in this digest is a $240.6 million firm-fixed-price delivery order awarded to QTC Medical Services Inc., a Leidos subsidiary, by the Department of Veterans Affairs for medical evaluation and screening services covering FY24. This is a civilian agency award with no defense-related content, and the signal is neutral at 5/10 strength. The contract is notable for its near-complete funding utilization (97% outlayed) and competitive win under full and open competition. Key watch items include follow-on task orders post-September 2024 and VA's sustained spending on medical evaluations. The primary risk is medium pricing risk on the fixed-price structure, though no bearish signals are flagged.

1 total filings
· daily

Significant Contract Modifications ($10M+) — September 22, 2026

The single contract in this period, a $240.6 million firm-fixed-price delivery order from the Department of Veterans Affairs to QTC Medical Services Inc. (a Leidos Holdings subsidiary), is entirely civilian and represents a near-fully funded, competitive win for medical evaluation services. The signal is neutral, as the contract is a one-year, non-optioned award with 97% of funding already outlayed, indicating execution is largely complete. The key risk is the lack of follow-on visibility beyond September 2024, while the bullish takeaway is Leidos’s ability to secure a large, competitive VA contract in a stable healthcare services budget environment. No defense-related contracts were awarded, underscoring a civilian-only procurement stream for this period.

1 total filings
· daily

Contract Deobligations Alert — September 22, 2026

In the September 22, 2026 contract deobligation stream, a single civilian award totaling $240.6 million was identified, with zero defense-related contracts. The Department of Veterans Affairs (VA) awarded QTC Medical Services Inc., a Leidos Holdings subsidiary, a firm-fixed-price delivery order for medical evaluation and screening services covering FY24, with 97% of funds already outlayed. This contract underscores the VA's sustained investment in healthcare services, though the near-complete funding utilization and neutral signal suggest limited near-term upside. The highest-conviction signal is the competitive win by QTC, reflecting its strong position in the VA medical evaluation market. Key watch items include follow-on task orders and VA budget trends for medical evaluations.

1 total filings
· daily

Contract Option Exercises — September 22, 2026

This digest covers a single contract option exercise from September 22, 2026, totaling $240.6 million, entirely civilian (Department of Veterans Affairs) with no defense-related awards. The dominant theme is sustained VA spending on medical evaluation services, with the highest-conviction signal being Leidos Holdings' subsidiary QTC Medical Services winning a competitive, firm-fixed-price delivery order that is 97% funded. Key risk: the contract's one-year term ended September 2024, and no follow-on awards are visible in this data, creating a revenue gap risk for Leidos if the VA does not re-compete or extend the work.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — September 22, 2026

The sole contract in this period is a $240.6 million firm-fixed-price delivery order awarded by the Department of Veterans Affairs to QTC Medical Services Inc., a subsidiary of Leidos Holdings, for medical evaluation and screening services. This is a civilian agency contract, with no defense-related awards in the period. The contract represents a competitive win under full and open competition, with 97% of the value already outlayed, indicating strong execution. The highest-conviction signal is the near-complete utilization of funds, which suggests high demand for VA medical evaluations but also signals a potential gap in future revenue for Leidos as the contract period has ended. Key risk: the contract's one-year performance period has concluded, and future revenue depends on follow-on awards or new contracts, which are not yet visible in the data.

1 total filings
· daily

High-Value Federal Grants ($5M+) — September 22, 2026

The sole contract in this digest is a $240.6 million firm-fixed-price delivery order awarded to QTC Medical Services Inc., a Leidos Holdings subsidiary, by the Department of Veterans Affairs for medical evaluation and screening services covering FY24. This is a purely civilian award with zero defense-related obligations, reflecting the VA's sustained investment in healthcare services rather than technology or defense programs. The contract shows near-complete funding utilization at $233.6 million outlayed (97%), indicating strong execution but also limited remaining upside. The highest-conviction signal is the competitive win under full and open competition, which underscores QTC's market position in the VA medical evaluation space, though the absence of options or set-asides limits forward visibility. Key risk: the one-year performance period ended September 30, 2024, so the lack of follow-on task orders in this digest raises questions about re-compete timing and potential revenue gaps for Leidos' health segment.

1 total filings
· daily

General Federal Contracts — September 22, 2026

This digest covers a single, large civilian contract: a $240.6 million firm-fixed-price delivery order from the Department of Veterans Affairs to QTC Medical Services Inc., a subsidiary of Leidos Holdings. The contract is for medical evaluation and screening services over FY24, with 97% of funds already outlayed, indicating near-complete execution. As a purely civilian award with no defense exposure, the signal is neutral, reflecting stable VA healthcare spending but limited growth catalysts. The key risk is the absence of follow-on contracts or options, creating a revenue cliff for Leidos' QTC unit after September 2024.

1 total filings
· daily

S&P 500 Technology Sector SEC Filings — September 22, 2026

The 10 filings from S&P 500 Technology constituents reveal a stark divergence in management conviction. While Adobe's Q3 FY2026 shows strong 12.9% YoY revenue growth, its massive $6.88B buyback program and rising liabilities ($18.2B) signal aggressive capital allocation that may be masking underlying operational shifts, including a 13.9% YoY decline in services revenue. The most critical development is a coordinated insider selling wave at CrowdStrike, where the CEO, CFO, President, and CAO collectively sold over $30M in shares within a single day, with the CEO executing sales under a 10b5-1 plan. This is compounded by a massive $298M stock sale by NVIDIA Director Mark Stevens, raising questions about valuation at current levels. KLA's filings are purely procedural, offering no financial insights. The portfolio-level pattern is clear: insiders at high-growth cybersecurity and semiconductor leaders are aggressively monetizing equity, while Adobe's management appears to be using buybacks to support the stock amidst a mixed operational picture.

9 high priority 1 medium 10 total filings
· daily

Nasdaq 100 Stocks SEC Filings — September 22, 2026

The five NASDAQ-100 filings reveal a bifurcated market: mega-cap AI infrastructure names are aggressively raising cheap debt (CoreWeave's $3.7B convertible) and insiders are monetizing at elevated valuations (NVIDIA director sold ~$300M), while Adobe shows decelerating growth and heavy buybacks masking margin pressure. CoreWeave's 2.875% coupon for 7-year convertible notes highlights the market's insatiable appetite for AI-related credit, with a 22.5% conversion premium signaling strong equity-linked demand. NVIDIA insider selling at $219.72 is a notable sentiment signal, though it represents a small fraction of the director's holdings. Adobe's 12.9% YoY revenue growth is offset by a 13.9% decline in services revenue and a $6.88B buyback that has increased leverage. Strategy Inc's small insider sales suggest a lack of conviction at current levels. The overarching theme is capital rotation: companies are leveraging balance sheets for AI growth and shareholder returns, while insiders take profits, creating a mixed tape for the index.

5 high priority 5 total filings
· daily

US Activist Hedge Fund Institutional SEC 13D 13G — September 22, 2026

The September 22, 2026 batch of 19 filings reveals a landscape of strategic positioning and passive accumulation, with notable activist and insider activity concentrated in a few key names. The most significant development is the board seat agreement at Group 1 Automotive (GPI) between Conifer Management and the company, signaling a potential catalyst for operational changes. Meanwhile, Fund 1 Investments has built a substantial economic exposure in Funko, Inc. (9.8% direct + 11.5% via swaps), suggesting a complex, potentially activist-oriented position. On the passive side, multiple institutional investors (Millennium, Hewlett Fund, RainForest Partners) have disclosed new stakes, while insiders at TriplePoint Venture Growth and Aeries Technology have made notable transactions. A key portfolio-level trend is the prevalence of 'mixed' sentiment in filings with insider transactions, indicating nuanced views. The data also highlights a capital allocation divergence, with some companies (e.g., Vista Credit) raising capital via private placements while others see insider buying (e.g., Aeries CEO). Overall, the filings point to a market where sophisticated investors are selectively deploying capital, seeking influence or value in specific situations.

10 high priority 9 medium 19 total filings
· daily

S&P 500 Financials Sector SEC Filings — September 22, 2026

The three filings in this S&P 500 Financials digest reveal a sector bifurcated between routine capital markets activity and operational friction. A major insider sale by AFLAC's 10% owner, Japan Post Holdings, signals potential strategic de-risking or capital repatriation, despite being executed under a 10b5-1 plan. In contrast, American Express's $1.3B securitization issuance (Series 2026-1) reflects healthy consumer credit demand and efficient access to capital markets, with a neutral market impact. A servicing error at Wells Fargo Commercial Mortgage Trust 2013-LC12, while low materiality, highlights ongoing operational risks in legacy CMBS structures. No period-over-period comparisons or forward-looking guidance were provided in these specific filings, limiting trend analysis. The key takeaway is a stable but cautious environment: large shareholders are trimming positions, while primary issuance remains robust, and legacy servicing issues persist.

1 high priority 2 medium 3 total filings
· daily

S&P 500 Energy Sector SEC Filings — September 22, 2026

The S&P 500 Energy sector experienced an extremely quiet session on September 22, 2026, with only one filing from Texas Pacific Land Corp (TPL) containing enriched data. The sole filing reveals a minor insider purchase by a 10% owner, Horizon Kinetics Asset Management, buying just 1 share at $349. While the transaction is immaterial in size, it signals continued confidence from a major long-term holder in a company that has been a standout performer in the energy sector. The lack of filings from the other 19 constituents suggests no material corporate events, earnings releases, or regulatory developments occurred on this date. The overall theme is one of calm, with no portfolio-level trends or sector-wide patterns to extract from the single data point. Investors should monitor for upcoming earnings calls and any delayed filings that may surface in the coming days.

1 high priority 1 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — September 22, 2026

This digest covers three filings from the Consumer Staples sector, all from two S&P 500 constituents: Hershey Co and Coca-Cola Co. The filings are predominantly routine and low-materiality, with no significant period-over-period trends, forward-looking guidance, or capital allocation changes reported in the enriched data. The most notable insider activity is a routine tax-withholding sale by Hershey's CEO, which is a standard corporate practice and not a bearish signal. Coca-Cola's filing is a routine debt maturity and delisting event, with no impact on its equity or operations. The overall theme is operational stability with no actionable catalysts or red flags. The digest highlights the lack of sector-wide trends from this small sample and focuses on the specific, low-impact nature of each event.

3 high priority 3 total filings